Marcos Langtry

Marcos Langtry is Head of Allogeneic Cell Therapy at Lonza. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions with TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he has acquired extensive experience with aseptically filled, biologic and cell therapy products.